Phaseline

Companies › Tiger Biosciences

Tiger Biosciences: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 4 Phase 4; Immunology, Metabolic and endocrine; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ACApatch™
Cellular, acellular, and matrix-like product (CAMP)
–Phase 4Pressure Ulcer; Venous Leg UlcerMay 2027
caregraFT™
Cellular, acellular, and matrix-like product (CAMP)
–Phase 4Pressure Ulcer; Venous Leg UlcerMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06999590ACApatch™Phase 4Pressure UlcerImmunologyMay 2027
NCT06999590caregraFT™Phase 4Pressure UlcerImmunologyMay 2027
NCT06826339ACApatch™Phase 4Venous Leg UlcerMetabolic and endocrineDec 2027
NCT06826339caregraFT™Phase 4Venous Leg UlcerMetabolic and endocrineDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Sequence LifeScience Applied Biologics Biocomposites R-Bio Wooshin Labottach

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.